Compare Merck & Co., Inc. (MRK) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Oatly Group AB - ADR — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Merck & Co., Inc. is far larger — about 1061.5× Oatly Group AB - ADR's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Oatly Group AB - ADR for 18 Days on average.
| MRK | OTLY | |
|---|---|---|
Market Cap | $351.28B | $330.93M |
Volume | 7,969,665 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $156.43 | $15.91 |
52-Week Low | $82.49 | $8.03 |
Typical Hold Time | 98 Days | 18 Days |
Enterprise Value | $398.04B | $835.34M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
OTLY trades at $10.38, up 0.1% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, showing progress toward profitability. The stock is supported by a consensus price target of $12.28 and positive news around Q2 2026 results, including a raised revenue outlook.
The outlook is cautiously optimistic as cost controls and sales growth may lead to positive EBITDA, but high debt and persistent cash burn pose risks. Analyst sentiment is mixed with 44% buy ratings, reflecting belief in the turnaround story amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
